In late September 2004, the cardiovascular risks identifiedin a placebo-controlled adenoma-prevention trial that was terminatedearly precipitated the voluntary withdrawal from the marketof the cyclooxygenase-2 (COX-2) inhibitor rofecoxib.1 Laterthat year, in another adenoma-prevention trial, the COX-2 inhibitor,celecoxib, was also associated with an increase in the riskof cardiovascular events.2 For this reason, on December 17,2004, the data and safety monitoring boards of two celecoxibtrials recommended stopping drug administration in the trials.2,3Articles describing the cardiovascular risks seen in the twoadenoma prevention trials were published rapidly.1,4 However,in the absence of evidence about the . . . [Full Text of this Article]
Source Information
From the Cardiovascular Health Research Unit, Departments of Medicine (B.M.P.), Epidemiology (B.M.P., J.D.P.), and Health Services (B.M.P.), University of Washington; and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (J.D.P.) both in Seattle.
Thomasset, S., Berry, D. P., Cai, H., West, K., Marczylo, T. H., Marsden, D., Brown, K., Dennison, A., Garcea, G., Miller, A., Hemingway, D., Steward, W. P., Gescher, A. J.
(2009). Pilot Study of Oral Anthocyanins for Colorectal Cancer Chemoprevention. Cancer Prevention Research
2: 625-633
[Abstract][Full Text]
Dance-Barnes, S. T., Kock, N. D., Moore, J. E., Lin, E. Y., Mosley, L. J., D'Agostino, R. B. Jr, McCoy, T. P., Townsend, A. J., Miller, M. S.
(2009). Lung tumor promotion by curcumin. Carcinogenesis
30: 1016-1023
[Abstract][Full Text]
Zell, J. A., Pelot, D., Chen, W.-P., McLaren, C. E., Gerner, E. W., Meyskens, F. L.
(2009). Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas. Cancer Prevention Research
2: 209-212
[Abstract][Full Text]
Krueger, K, Lino, L, Dore, R, Radominski, S, Zhang, Y, Kaur, A, Simpson, R, Curtis, S
(2008). Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis
67: 315-322
[Abstract][Full Text]
Keku, T. O., Amin, A., Galanko, J., Martin, C., Schliebe, B., Sandler, R. S.
(2008). Apoptosis in Normal Rectal Mucosa, Baseline Adenoma Characteristics, and Risk of Future Adenomas. Cancer Epidemiol. Biomarkers Prev.
17: 306-310
[Abstract][Full Text]
Sedjo, R. L., Byers, T., Barrera, E. Jr., Cohen, C., Fontham, E. T. H., Newman, L. A., Runowicz, C. D., Thorson, A. G., Thun, M. J., Ward, E., Wender, R. C., Eyre, H. J., for the ACS Cancer Incidence & Mortality Ends Comm,
(2007). A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015. CA Cancer J Clin
57: 326-340
[Abstract][Full Text]
Bock, J. M., Menon, S. G., Sinclair, L. L., Bedford, N. S., Goswami, P. C., Domann, F. E., Trask, D. K.
(2007). Celecoxib Toxicity Is Cell Cycle Phase Specific. Cancer Res.
67: 3801-3808
[Abstract][Full Text]
Armstrong, D. J.
(2007). Celecoxib and CVS risk--lessons from the APC and PreSAP studies. Rheumatology (Oxford)
46: 561-562
[Full Text]
Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D.
(2007). Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED
146: 376-389
[Abstract][Full Text]
Hawk, E., Viner, J. L.
(2007). The Adenoma Prevention with Celecoxib and Prevention of Colorectal Sporadic Adenomatous Polyps Trials: Stepping Stones to Progress. Cancer Epidemiol. Biomarkers Prev.
16: 185-187
[Full Text]
Levine, J. S., Ahnen, D. J.
(2006). Adenomatous Polyps of the Colon. NEJM
355: 2551-2557
[Full Text]
Jewett, A., Head, C., Cacalano, N.A.
(2006). Emerging Mechanisms of Immunosuppression in Oral Cancers. JDR
85: 1061-1073
[Abstract][Full Text]